[Pharmacological characteristics and clinical study results of Selexipag (Uptravi


Journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
ISSN: 0015-5691
Titre abrégé: Nihon Yakurigaku Zasshi
Pays: Japan
ID NLM: 0420550

Informations de publication

Date de publication:
2021
Historique:
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 11 5 2021
Statut: ppublish

Résumé

Selexipag (Uptravi

Identifiants

pubmed: 33952848
doi: 10.1254/fpj.20092
doi:

Substances chimiques

Acetamides 0
Antihypertensive Agents 0
Pyrazines 0
Receptors, Epoprostenol 0
Tablets 0
selexipag 5EXC0E384L

Types de publication

Clinical Trial, Phase II Journal Article

Langues

jpn

Sous-ensembles de citation

IM

Pagination

178-186

Auteurs

Keiichi Kuwano (K)

Research & Development Division, Nippon Shinyaku Co., Ltd.

Keiji Kosugi (K)

Research & Development Division, Nippon Shinyaku Co., Ltd.

Chiaki Fuchikami (C)

Research & Development Division, Nippon Shinyaku Co., Ltd.

Shunji Funaki (S)

Global Business Division, Nippon Shinyaku Co., Ltd.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH